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ABSTRACT Human y heavy chain disease (HCD) is charac-
terized by the presence in serum of a short monoclonal Ig y chain
unattached to light chains. Although most HCD proteins have in-
ternal deletions, in some the defect is NH2-terminal. The OMM
v3 HCD serum protein is of the latter type, having undergone an
extensive NH2-terminal deletion with a sequence starting within
the hinge. A cell line synthesizing the OMM protein has enabled
us to study the biogenesis ofthe abnormal molecule. In vitro trans-
lation of isolated mRNA yields a protein containing a hydrophobic
NH2-terminal leader sequence. In the intact cell, the precursor
molecule is processed normally to yield a protein with an NH2-ter-
minal sequence homologous to the beginning of the variable (V)
region. The nucleotide sequence of cDNA prepared from the
OMM mRNA encodes a 19-amino acid leader followed by the first
15 residues of the V region. An extensive internal deletion encom-
passes the remainder of the V and the entire CHI domain. Im-
mediately following the short V region, there is information in the
cDNA for the entire normal hinge. The primary synthetic product
is thus an internally deleted molecule that undergoes postsynthetic
degradation to yield the NH2-terminally deleted serum protein.
The structure of the OMM mRNA suggests that the protein ab-
normality results from a partial gene deletion rather than defec-
tive splicing.
In heavy chain disease (HCD), a naturally occurring human
lymphoproliferative disorder, variant monoclonal Ig heavy (H)
chain fragments are found in the patients' serum or urine. HCD
proteins of the 'y class have been studied in detail, although
those ofthe a and.y classes have also been described (1, 2). The
abnormal serum proteins of the y class all show complete dele-
tion of the CHi domain of the constant (C) region. Additional
features separate the proteins into three types. Most ofthe vari-
ant molecules studied to date have a normal or aberrant NH2-
terminal variable (V)-region sequence ofvariable size, followed
by an extensive internal deletion encompassing most of the V
region and the CHL domain. Normal structure usually resumes
at the beginning ofthe hinge. In the second group, the deletion
continues through the hinge, with normal sequence starting in
the CH2 domain. Least frequently, y HCD proteins are found
that lack the entire V and CHI domains. In such cases, the serum
protein sequence starts within the hinge, and it is therefore
unclear whether the molecules are of degradative or synthetic
origin.
A y3 HCD protein was isolated from the serum of patient
OMM and shown to have a monomeric molecular weight of
40,000 and an unblocked NH2 terminus (3). It had undergone
an extensive NH2-terminal deletion with a homogeneous se-
quence starting within the hinge. In addition to the HCD pro-
tein, the patient's serum also contained a homogeneous (y3)2A2
molecule with apparently normal H and light (L) chains (4).
Because the HCD protein was NH2-terminally deleted, it was
not possible to tell whether it was the product of partial pro-
teolytic degradation.
A permanent cell line, established from the peripheral blood
of the patient, gave us the opportunity to study the HCD pro-
tein at several stages in its biosynthetic history (5).
Analysis of the radiolabeled molecules synthesized by the
cells and precipitated with specific anti-y and anti-L chain anti-
sera showed that the line produced only the HCD protein and
that the intracellular and secreted forms were identical in mo-
bility on NaDodSO4/polyacrylamide gels. Short-term labeling
studies did not reveal degradation of a normal-sized H chain to
yield the short polypeptide.
mRNA was extracted from the cells and shown, by sucrose
gradient centrifugation, to be smaller than the message coding
for a normal 'y3 chain (15.5S vs. 17S, respectively). When trans-
lated in vitro by using a protein-synthesizing extract derived
from wheat germ (6) or reticulocytes (7), the mRNA directed
the synthesis of a protein 2,000 daltons larger than the ungly-
cosylated protein synthesized by the cells in the presence of the
glycosylation inhibitor 2-deoxyglucose. Such an extension cor-
responds to approximately 20 additional amino acids.
MATERIALS AND METHODS
mRNA Isolation. The OMM cells were maintained in cul-
ture, in RPMI-1640 medium with 5% fetal calfserum. For prep-
aration ofmRNA (5), cells were harvested from spinner cultures
at a density of 5 X 105 per ml and frozen at -800C. In early
preparations, cytoplasmic RNA was extracted by using the
NaDodSO4/phenol/chloroform method. In later work, total
cellular RNA was prepared by the guanidine thiocyanate pro-
cedure (8). The poly(A)-containing mRNA fraction was isolated
by chromatography on oligo(dT)-cellulose (P-L Biochemicals)
(5).
In Vitro Translation. For preparation of the in vitro trans-
lated 0MM protein (OMMTr) (5), mRNA was added to wheat
germ lysate (6) in the presence of [3S]methionine, [3H]leucine,
or [3H]phenylalanine, and the radiolabeled OMMTr was pre-
cipitated from the translation mixtures by the addition of anti-
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human y antiserum plus carrier human IgG. After extensive
washing, the OMMTr specific precipitates were dissolved in 5
M guanidine/0. 1 M Tris HCl, pH 8.3. The disulfide bonds were
reduced by incubation with 5 mM dithiothreitol for 1 hr at 370C
and alkylated with 10 mM iodoacetamide for an additional hour.
In preparation for amino acid sequence analysis, the completely
reduced protein was dialyzed extensively against 1 M HOAc.
Amino Acid Sequence Analysis. Amino acid sequences were
determined automatically with a Beckman model 890C se-
quencer by the method of Edman and Begg (9). The positions
of the radiolabeled amino acids were determined by measuring
radioactivity at each degradation step.
Pronase Digestion. Digestion by Pronase (Sigma) (10) of the
completely reduced and alkylated HCD protein secreted by the
cells was performed in 0.1 M NH4HCO3, pH 8.2, for 3 hr at
37TC at an enzyme-to-substrate ratio of 1:50 (wt/wt). The digest
was applied to a Dowex AG5OW-X2 (Bio-Rad) column in water
to separate the peptides containing pyrrolidone carboxylic acid.
Nucleic Acid Sequence Analysis. Sequencing procedures
were those of Maxam and Gilbert (11), except that a modified
G+A cleavage reaction was used (12). Restriction endonucle-
ase-digested DNA was labeled either at protruding 3' ends by
using [a-32P]3'-dATP (cordycepin; New England Nuclear) in
the presence of terminal deoxynucleotidyltransferase (P-L Bio-
chemicals) or at recessed 3' ends by using the four deoxynu-
cleoside [a-32P]triphosphates (New England Nuclear) in the
presence of Escherichia coli DNA polymerase I (Klenow frag-
ment; Boehringer-Mannheim). After labeling, fragments la-
beled at one end were produced either by redigestion ofdouble-
stranded DNA with a different restriction endonuclease or by
strand separation on 5% polyacrylamide gels (11). After deg-
radation reactions, the DNA fragments were electrophoresed
on either 32 X 40 X 0.04 cm 25% polyacrylamide sequencing
gels for the separation of oligonucleotides I to 35 bases in length
or 32 X 80 x 0.04 cm 5% polyacrylamide gels for separation
of oligonucleotides containing 30 or more bases.
Preparation ofcDNA Clones. To prepare a fraction enriched
in the OMM message, the total poly(A)-containing RNA was
size-fractionated by centrifugation through 10-40% sucrose
gradients. RNA molecules were selected that sedimented in the
15.5-16S region, because previous work had shown that cell-
free translation of these fractions yielded bona fide HCD pro-
tein (5). Procedures for the preparation ofrecombinant plasmids
from the enriched mRNA molecules were as described by Stein-
metz et aL (13) and are summarized as follows: cDNA copies of
the messages in the enriched fractions were made by extending
oligo(dT) primers with avian myeloblastosis virus reverse tran-
scriptase (obtained from J. Beard, Life Sciences, St. Petersburg,
FL). After alkaline hydrolysis of the RNA, double-stranded
cDNA was prepared by incubation of the single strands with
DNA polymerase I and the four deoxynucleoside triphosphates.
The resulting hairpin loop was cleaved with S1 nuclease. The
double-stranded molecules, tailed at the 3' ends with poly(dC)
in the presence of terminal deoxynucleotidyltransferase, were
inserted in the Pst I endonuclease site of plasmid pBR322 sim-
ilarly tailed with poly(dG). E. coli strain MC1061 was trans-
formed with the recombinant plasmids by using the procedure
of Kushner (14). Successful transformations were identified us-
ing the high density screening method of Hanahan (15). Pre-
liminary studies in our laboratory established conditions under
which human immunoglobulin genomic sequences would hy-
bridize with either genomic or cDNA clones containing ho-
mologous murine Ig DNA sequences (unpublished results). A
murine (BALB/c) genomic clone (Y42) containing a 6.7-kilobase(kb) EcoRI fragment which included the y2b constant region
sequences was obtained from M. Davis and S. Kim ofCalifornia
Institute of Technology. DNA from the clone was digested with
EcoRI and the 6.7-kb fragment was isolated by agarose gel elec-
trophoresis and benzoylated DEAE-cellulose chromatography.
Two micrograms of the isolated 6.7-kb fragment were nick-
translated to yield a 32P-labeled molecule with a specific activity
of 6 x 107 cpm/tkg. The labeled probe was used for colony
hybridization (15).
RESULTS AND DISCUSSION
Amino Acid Sequence of the OMM Translation Product and
Cellular Protein. When the OMM mRNA was added to wheat
germ lysate in the presence of [3S]methionine, [3H]leu-
cine, or [3H]phenylalanine, a radiolabeled translation product
(OMMT,), specifically precipitable with anti-y antiserum, was
obtained, and the amino acid sequence of the NH2-terminal
region was determined as described in Materials and Methods.
OMMTr contains methionine at the NH2 terminus followed by
a hydrophobic region containing phenylalanine at positions 6
and 7 and leucine at positions 4, 8, 9, 10, and 18. Such a struc-
ture corresponds in length, position, and hydrophobicity to the
leader sequences found at the NH2 termini ofnewly synthesized
secretory proteins (16).
In contrast to the in vitro translated material, the cytoplasmic
protein contained a blocked NH2 terminus. To determine the
NH2-terminal residues, unlabeled HCD protein secreted by
the cultured cells was isolated by specific adherence to an in-
soluble immunoabsorbent column of rabbit anti-human IgG.
The HCD protein eluted from the column was digested with
Pronase as described in Materials and Methods. A dipeptide
was obtained that contained pyrrolidone carboxylic acid (a cyclic
form of glutamine or glutamic acid) followed by valine. Human
V regions of subgroups I and II commonly start with such a se-
quence. Unlike the cellular protein, the serum protein began
with a sequence starting at the glycine, 7 residues past the nor-
mal beginning of the 'y3 hinge (3). The amino acid sequences
of the three biosynthetic forms of the OMM protein are shown
in Fig. 1, with the normal y3 hinge sequence aligned for
comparison.
We had previously determined that the message coding for
the OMM protein was smaller in size than that coding for a
normal y chain (5). We therefore interpret the data in Fig. 1
to indicate that the short cytoplasmic mRNA codes for a pre-
cursor HCD protein having a deletion and from which the
leader piece is cleaved in a normal way by the intact cell to
produce a molecule whose NH2 terminus is Glx-Val. Such a
sequence corresponds to the normal NH2 terminus of the V
region. The similarity in size between the cellular and serum
proteins, as determined by electrophoretic mobility on Na-
DodSO4/polyacrylamide gels, indicated that only a small por-
tion of normal V region could be present and that the deletion
would, therefore, include most of the V and the CH1 domain,
with normal sequence resuming at the hinge. Thus, when se-
creted, the OMM HCD protein resembles the majority of in-
ternally deleted HCD molecules. Cleavage of the cellular pro-
tein between the 6th and 7th residues of the hinge (Leu-Gly)
would produce the NH2 terminus of the protein found in the
patient's serum. It was previously determined that the hinge
region of intact y3 H chains is particularly sensitive to the action
ofcommon proteases (17). The replacement ofthe normal V and
CH1 domains by a short V-region sequence immediately pre-
ceding the hinge may expose potential proteolytic cleavage sites
in that region that would not otherwise be available for enzy-
matic attack.
Preparation of cDNA Clones from the y3 HCD mRNA.
pBR322 plasmids containing DNA inserts complementary to
OMM cellular messages were prepared and used to transform
E. coli strain MC1061 as described in Materials and Methods.
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Leader Sequence I Short V Region [ Hinge
In Vitro
Translation
Product (OMMTr)
Cell Protein
Met--Leu-PhePheLeuLeuLeu-------Leu .................................
1<GluVal ......................
GlyAspThrThr...
GluLeuLysThrProLeuGlyAspThrThr...
FIG. 1. The NH2-terminal sequences of the three different biosynthetic forms of the OMM HCD protein (-, undetermined amino acids; <Glu,
pyrrolidone carboxylic acid). The sequence at the beginning of the normal y3 hinge region (17) is shown for comparison with the NH2-terminal
sequence of the serum protein.
Four of approximately 6,000 recombinant clones clearly con-
tained DNA sequences complementary to the mouse y2b DNA
used as a hybridization probe. Plasmid DNA from the four
clones was bound to nitrocellulose filters and used to select
mRNA molecules from total poly(A)-containing RNA extracted
from the OMM cells (18). The duplexes were melted and the
mRNA was translated in cell-free translation systems extracted
from both wheat germ and reticulocytes (6, 7). Immunologic
precipitation of the labeled translation products followed by
NaDodSO4/polyacrylamide gel electrophoresis revealed that
the mRNA hybridizing with the plasmid DNA coded for the y3
HCD protein.
DNA from each of the clones (designated POMMA, -B, -C,
and -D) was digested with Pst I. The sizes of the cDNA inserts,
as determined by agarose gel electrophoresis, were 1.8, 1.0,
0.7, and 0.5 kb, respectively. The clones with the two largest
inserts, A and B, were chosen for further study.
Nucleotide Sequence of OMM cDNA. The amino acid se-
quence deduced from the nucleotide sequence of the OMM
cDNA (Fig. 2) confirms and extends the results obtained by
Leader
...... CCUGGACCUCCUGUGCAAGAAC AUG AAA CAN CUG UGG UUC UUC CUU CUC CUG GUG GCA GCU CCC AGA UGG GUC CUG UCC
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp Val Leu Ser
-19 -3 -2 -1
V Region Hinge
CAG GUG CAC CUG CAG GAG UCG GGC CCA GGA CUG GGG AAG CCU CCA GAG CUC AAA ACC CCA CUU GGU GAC ACA ACU CAC ACA UGC CCA CGG
Gln Val His Leu Gln Glu Ser Gly Pro Gly Leu Gly Lys Pro Pro Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg
1 2 3 15 216 217 218 219 220 221 222 223 224 225 226 227 228
UGC CCA GAG CCC AAA UCU UGU GAC ACA CCU CCC CCG UGC CCA CGG UGC CCA GAG CCC AAA UCU UGU GAC ACA CCU CCC CCA UGC CCA CGG
Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
229 230
CH2
UGC CCA GAG CCC AAA UCU UGU GAC ACA CCU CCC CCG UGC CCN NNG UGC CCA GCA CCU GAA CUC UUG GGA GGA CCG UCA GUC UUC CUC UUC
Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
231 243
CCC CCA AAA CCC AAG GAU ACC CUU AUG AUU UCC CGG ACC CCU GAG GUC ACG UGC GUG GUG GUG GAC GUG AGC CAC GAA GAC CCN NNN GUC
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Val
244 273
CAG UUC MG UGG UAC GUG GAC GGC GUG GAG GUG CAU AAU GCC AAG ACA AAG CUG CGG GAG GAG CAG UAC AAC AGC ACG UUC CGU GUG GUC
Gln Phe Lys Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Leu Arg Glu Glu Gln Tyr Asn Ser Thr Phe Arg Val Val
274 303
AGC GUC CUC ACC GUC CUG CAC CAG GAC UGG CUG AAC GGC AAG GAG UAC AAG UGC AAG GUC UCC AAC AAA GCC CUC CCA GCC CCC AUC GAG
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
304 333
CH3
AAA ACC AUC UCC AAA GCC AAA GGA CAG CCC - 36 N - GAG GAG AUG ACC AAG AAC CAA GUC AGC CUG ACC UGC CUG GUC AAA GGC UUC
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
334 341 342 356 372
UAC CCC AGC GAC AUC GCC GUG GAG UGG GAG AGC MU GGG CAG CCG GAG AAC AAC UAC AAC ACC ACG CCU CCC AUG CUG GAC UCC GAC GGC
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly
373 402
UCC UUC UUC CUC UAC AGC AAG CUC ACC GUG GAC AAG AGC AGG UGG CAG CAG GGG AAC AUC UUC UCA UGC UCC GUG AUG CAU GAG GCU CUG
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile Phe Ser Cys Ser Val Met His Glu Ala Leu
403 432
End of CH3
CAC AAC CGC UAC ACG CAG AAG AGC CUC UCC CUG UCU CCG GGU AAA UGA GUGCCAUGGCCGGCAAGCCCCCGCUCCCCGGGCUCUCGGGGUCGCGCGAGGAUGC
His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys End
433 446
UUGGCACGUACCCCGUGUACAUACUUCCCAGGCACCCAGCAUGGAAAUAAAGCACCCAGCGCUGCCCUGGAAAAAAAAAAAA - GC linker
FIG. 2. Nucleotide sequence of the OMM HCD mRNA (N, nucleotide not determined). The deduced amino acid sequence is shown beneath the
nucleotide sequence. The numbers correspond to amino acids of the yl protein Eu (19). The nucleotide sequence was derived primarily from the
POMMB cDNA clone, which contained the sequence starting with the last 9 nucleotides of the leader through the 3' untranslated region. The entire
sequence of the leader was determined from the larger POMMA clone, which also contained the POMMB sequence, as determined by restriction
enzyme mapping and partial nucleotide sequencing.
Serum Protein
Normal Y3
Hinge
I
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direct amino acid sequence analysis of the OMM protein. The
leader encompasses 19 amino acids and ends with a serine res-
idue, as do many of the published mouse H- and L-chain lead-
ers. The highly hydrophobic character is apparent from the
complete sequence. The 15 amino acids immediately following
the leader are clearly homologous to the first 15 residues of
human H-chain V regions. A comparison with the subgroup II
protein NEWM (20) shows identity at 11 ofthe first 15 residues.
The differences at the remaining four positions can be ac-
counted for by single-base changes.
The direct amino acid sequence data did not define the spe-
cific point where normal structure resumes after the deletion.
Because the serum protein appeared to be the product of lim-
ited NH2-terminal proteolysis, the NH2-terminal glycine was
not likely to be the true COOH-terminal boundary of the dele-
tion. It is clear from the OMM cDNA nucleotide sequence that
the coding information for the entire normal hinge region is
present in the cytoplasmic message, hence the deletion extends
from amino acid 16 in the V region through residue 215 [Eu
numbering (19)], which marks the end of the CH1 domain.
The amino acid sequence deduced from the OMM cDNA
agrees with published y3 protein sequences (21, 22) with the
exception of seven residues. Positions 283 and 386 involve Glu/
Gln interchanges which probably reflect uncertainties in the
protein sequence. At position 291, a residue not involved in
subclass determination, a single base change leads to the re-
placement of proline with leucine. The remaining four variant
amino acids, 296, 339, 384 and 436, are identical to residues
found in the normal human yl sequence.
The heavy chain of a recently described intact y3 myeloma
protein, GOE (23), also contains yl residues at three of the
above four positions, the fourth residue being undetermined.
These data suggest that the GOE and OMM proteins may be
allelic forms of y3 or may represent another 'y subclass, the
product of a separate y3-like gene. The similarity between
OMM and the H chain of the GOE protein, an apparently nor-
mal Ig molecule, suggests that most of the discrepancies be-
tween the published y3 protein sequence and that deduced
from the OMM cDNA can be attributed to a naturally occurring
sequence polymorphism.
The normal y3 hinge region consists of the quadruplication
ofa basic unit 15 amino acids in length. The first ofthe four units
includes an addition of two amino acids and is homologous but
not identical to the others, whereas the latter three units are
exact repetitions. Because it is thought likely that the y3 hinge
evolved by quadruplication ofthe ancestral 15-residue unit (17),
we expected to see a greatly conserved codon usage when com-
paring a particular position in one unit with the same position
in the other three. This proved to be correct. Except for one
silent base change in a proline codon, the nucleotide sequences
ofthe last three repeat units are identical. In the first unit, with
the exception of one position, the amino acid sequence diver-
gence reflects only single base changes in the codons.
Y3 HCD cDNA
Y4 genomic DNA
Y3 HCD cDNA
Y4 genomic DNA
Immediately before the stop codon in the cDNA sequence,
there is information for an additional lysine that is not present
in any of the published y3 amino acid sequences. Because the
cDNA is a direct copy of the mature cytoplasmic message, the
extra codon is presumably translated. The nucleotide sequences
of the human y4 (24) and mouse yl (25), y2a (26, 27), and 'y2b
(28, 29) genes also encode information for a COOH-terminal ly-
sine not present in the mature proteins. Apparently, the lysine
is removed from Ig H chains of both species postsynthetically.
The sequence of the OMM cDNA 3' untranslated region is
shown in Fig. 3, compared to the corresponding region in the
human y4 gene (24). The two sequences differ in 5 out of 133
nucleotides, with no additions or deletions being necessary to
maintain homology. The sequence A-A-T-A-A-A, thought to be
a signal for poly(A) addition (30), is identically positioned in both
sequences. In the POMMB cDNA clone, poly(A) was added 19
nucleotides 3' to the A-A-T-A-A-A region. The POMMA clone
contained a different poly(A) addition site eight nucleotides 3'
from the POMMB site. Because both cDNA clones have the
same extensive internal deletion in the coding region, it is prob-
able that the mRNAs that served as templates for the cDNA
copies were transcripts of the same gene. Published nucleotide
sequences of the cDNAs coding for mouse Ig H chains indicate
that in the y2a (31) and y2b (32) subclasses poly(A) is added at
a position homologous to that seen in the POMMA clone. The
site for poly(A) addition in the cDNA coding for an intact yl
chain (33) is located one base 3' to the POMMB site, although
the deleted yl H chain IF-2 (34) has poly(A) added at the
POMMA site. These data suggest that the finding of two dif-
ferent functional poly(A) addition sites in the OMM RNA tran-
scripts is not related to the structural abnormality in the coding
region. Multiple poly(A) addition sites have also been described
for the murine dihydrofolate reductase (35), a-amylase (36), and
Ig ,u-chain (37) genes, although in the latter case the two sites
are associated with the membrane and secretory forms of the
message. It thus appears that poly(A) addition is not fixed to one
site per gene.
Molecular Events Underlying Synthesis of the Protein Hav-
ing the Deletion. Because immunochemical and amino acid se-
quence analyses of the HCD proteins revealed that the dele-
tions encompassed whole domains with resumption of normal
structure at the beginning ofthe hinge, it was hypothesized that
the hinge represents a separate genetic element (38). Structural
studies ofgerm-line and active mouse (25-29, 39, 40) and germ-
line human (24) y-chain genes revealed that the DNA coding
for the V region and the domains of the constant region were
separated by noncoding intervening sequences (IVS). Hence,
the hinge region is coded by a separate gene segment. The en-
tire H-chain unit is transcribed into a single precursorRNA from
which the noncoding sequences are removed, and the coding
regions are spliced together to yield the cytoplasmic mRNA.
In the HCD cell line, a generalized abnormality of the splicing
mechanism is very unlikely, because the mRNAs coding for
GTGCCATGGCCGGCAAGCCCCCGCTCCCCGGGCTCTCGGGGTCGCGCGAGGATGCTTGGCACGTAC
1 66
Poly(A) addition sites
POMMB POMMA
CCCGTGTACATACTTCCCAGGCACCCAGCATGGAAATAAAGCACCCAGCGCTGCCCTGGICCCCTGCI
6CG7 CTACATACTTCCCAGAbICAATGGAAATAAAGCACCCACCAGCCCTGGGCCCG1...
67 133
FIG. 3. The 3' untranslated region of the OMM HCD cDNA compared to that of human y4 genomic DNA (24) (* indicates difference between
the two sequences).
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other cell proteins are correctly spliced. A mutation or deletion
resulting in an altered or missing splice site could force a normal
splicing system to select another available position and thus join
two coding regions that would not normally be contiguous. It
has been demonstrated that this is the case in both the murine
Ig H-chain variant IF-2 (41) and a clone of the murine plas-
macytoma MPC-li that synthesizes an L-chain fragment
(42-44).
Examination ofavailable human H-chain V-region amino acid
sequences (45) reveals no case in which there is a proline at
residue 15. The residues commonly found at position 15 are:
for VH1, Gly (8 out of 8); for VH2, Thr (3 out of 5), Lys (1 out
of 5), Ser (1 out of 5); for VH3, Gly (48 out of 48). Hence, it is
possible that the proline in position 15 of the OMM protein is
abnormal and may reflect an event that created the codon CCA
followed by a sequence capable of serving as the donor site of
a splice junction. The creation of a new donor site would allow
the joining of the short V-gene fragment to the hinge exon. To
yield the amino acid sequence observed, at least two normal
donor sites, those at the ends of the joining (J) and the CH1
exons, had to be bypassed. The most likely explanation to ac-
count for these observations is a substantial DNA deletion. The
definition of the actual event awaits the determination of the
nucleotide sequence of genomic clones isolated from the HCD
cells.
The present data now make it appear likely that NH2-ter-
minally deleted HCD serum proteins are synthesized initially
as internally deleted molecules and have biosynthetic histories
similar to the history of the OMM serum protein. A possible
scenario for the generation of the aberrant proteins could begin
with a deletion or mutation at the DNA level that results in
altered or missing splice sites in the primary nuclear RNA tran-
script. This would cause the splicing system to align coding re-
gions that are not normally contiguous. Thus, a short message
would be formed in which a large part of the normal coding
region is deleted. Nevertheless, the molecule would be entirely
capable of directing translation of an internally deleted protein
that would be processed normally to yield an internally deleted
secretory product. In some cases, the abnormal NH2 terminus
may become the substrate for proteolytic enzymes in the serum,
resulting in proteins with apparent NH2-terminal deletions.
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